Genmab — Marts 2025

[E_L]

AACR25 5788 / 15 - Molecular profiling of NSCLC patients associates CT-based radiomic features with a tumor microenvironment favorable for immunotherapy https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/1563

[E_L]

AACR25
3093 / 1 - Molecular profiling of tisotumab vedotin-treated patients identified immune pathways associated with clinical activity, supporting the multimodal mechanism of action https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/7265

[E_L]

AACR25 6075 / 16 - The combination of an EpCAMx4-1BB bispecific antibody with PD-1 blockade exhibits antitumor activity in a murine tumor model unresponsive to each individual antibody https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/7895

[E_L]

AACR25 6239 / 3 - Modeling and simulation of CRS events in low-risk populations with a rapid ramp-up SUD regimen of epcoritamab https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/5717

[E_L]

AACR25 6880 / 24 - Rinatabart sesutecan (PRO1184) in combination with standard-of-care therapy exerted potentiated antitumor activity in preclinical cancer models https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/7537

[E_L]

AACR25
CT233 / 2 - A phase 2b study of subcutaneous amivantamab with lazertinib as first-line treatment, or with chemotherapy as second-line treatment, for EGFR-mutated non-small cell lung cancer (NSCLC): COPERNICUS https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/10602

[E_L]

AACR25 7331 / 17 - Antitumor activity of amivantamab in diffuse pleural mesothelioma https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/8400

[E_L]

AACR25 3644 / 6 - Mechanistically explainable AI model for predicting synergistic cancer therapy combinations https://www.abstractsonline.com/pp8/?utm_source=salesforce-marketing-cloud&utm_medium=email&utm_campaign=AM25+-+Itinerary+Planner&utm_term=PROGRAM+PLANNER#!/20273/presentation/3279

[E_L]

Genmab Announces Initiation of Share Buy-Back Program https://ir.genmab.com/news-releases/news-release-details/genmab-announces-initiation-share-buy-back-program-4

[lahn1]

On the 5788 abstract, Way above my pay grade BUT seems this could be a game changer for Acasunlimab ! Improve efficacy outcomes by selecting better responders.
Enhance safety by avoiding hyper-toxic patients.
Differentiate acasunlimab from competitors in the 4-1BB space. And be implemented in the ongoing ph3 study as a biomarker

[LP90]

Godmorgen lad os håbe aktie tilbagekøb
er det der vender trenden

[JKY_VH]

Ja lad os det LP90. Det er i hvert fald et godt tidspunkt at aktivere tilbagekøbsprogrammet og god morgen:-)

[transalp]

Ja de for da aktier for pengene..

[transalp]

Go morgen..

[JKY_VH]

Aktietilbagekøbsprogrammet på op til 4 mia. kr. løber frem til den 10 juli 2025. Der skal altså handles en del aktier de næste 3,5 måneder.

[JKY_VH]

Mon de regner med gode nyheder indenfor den tidshorisont, således at aktien er selvkørende herefter?

[Darvin]

Thanks E L Great to see the pace and quality Genmab is showing with their pipeline. They are managing their resources extremely well.

[E_L]

And their resources have exploded over the last few years with the immens growth in staff. Someone mentioned a concern the other day about the own R&D capacity of Genmab, with all the focus on Rina-S and the disappointment of Hexabody-CD38.

[E_L]

I think we should see much of that in the light of the continued questions by investors about a potential revenue gap in the early 2030s, so Genmab has tried to steer investors attention that way.

[E_L]

But that doesn't mean that they stopped their R&D, on the contrary; we should expect to see a vastly larger stream of R&D news than in the years before i would think.